ImproviNg rEnal Outcomes Following Coronary angiograPhy and/or percuTaneoUs coroNary intErventions

Launched by MONTREAL HEART INSTITUTE · Jun 15, 2021

Keywords

ClinConnect Summary

The NEPTUNE trial is studying a new way to help protect patients' kidneys during heart procedures, specifically when using a special dye called contrast media. This dye is often used during tests like coronary angiograms and procedures to open blocked arteries, which can sometimes lead to kidney problems. The trial is testing a hydration strategy based on specific measurements to see if it can prevent kidney injury related to these procedures.

To participate in this trial, you need to be at least 18 years old and scheduled for a coronary angiogram or a procedure to open heart arteries. You should also be willing to come to study visits and have a life expectancy of at least six months. However, if you are experiencing severe heart issues, have had certain treatments recently, or have specific heart conditions, you may not be eligible. If you join the trial, you will receive careful monitoring and support to help keep your kidneys healthy during your heart procedure.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age ≥18 years;
• • Planned coronary angiogram and/or PCI;
• • Willingness to participate and to attend study visits;
• • Expected life expectancy ≥6 months.
• Exclusion Criteria:
• • Cardiogenic or non-cardiogenic shock at the time of the procedure;
• • Emergent procedures (e.g. STEMI);
• • Iodine-based contrast media received within 2 days;
• • Presence of Intra-Aortic Balloon Pump (IABP);
• • Cardiac arrest within 24 hours;
• • Pre-procedural AKI defined using the modified KDIGO criteria within 7 days;
• • Renal replacement therapy;
• • Severe aortic or mitral disease;
• • LVEF \<30%.